Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected Adolescents
Status:
Completed
Trial end date:
2017-10-23
Target enrollment:
Participant gender:
Summary
The primary objective of this study is to evaluate the safety and tolerability of
elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF) in HIV-infected
virologically suppressed adolescents 12 to < 18 years of age.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Gilead Sciences
Treatments:
Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination